

Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease

Planning Phase II Trial

VANCOUVER, BC – (November 13, 2018) – Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “**Company**” or “Nash Pharma”) is pleased to announce that one of its lead compounds for Inflammatory Bowel Disease (“IBD”) NP-178 showed positive results in a recently completed study investigating its therapeutic effects in an ulcerative colitis mouse model. NP-178 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy. Repurposing drugs offer several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.

Data from this study demonstrated statistically significant improvements in multiple measurements over multiple timepoints relevant to ulcerative colitis including:

- Body weight, stool consistency, colon length and weight ratios and occult positivity ($p < 0.001$ to $p < 0.05$)
- The drug compared very favourably to the control, 5-ASA, the current standard of care for IBD.
- No negative side effects were observed.
- NP-178 is a repurposed, orally delivered neurological drug.

“The IBD market segment represents an enormous unmet medical need globally and there is a particular interest in orally delivered compounds exhibiting new mechanisms of action,” said Christopher J. Moreau CEO of Nash Pharma. “We plan to present our preclinical *in vivo* IBD results at an upcoming conference and will update the market on plans for a Phase IIa study for our leading repurposed IBD candidate in 2019 pending additional results shortly.”

About IBD

The Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028 Report shows that the global inflammatory bowel diseases (IBD) drug market is estimated at \$6.7bn in 2017 and \$7.6bn in 2023. Biologic therapies held 57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of 6.3% from 2018-2023.

About Nash Pharmaceuticals Inc.

Nash Pharma is a wholly owned subsidiary of Breathtec Biomedical Inc. Nash Pharma is a clinical stage pharmaceutical development company focused on drug repurposing in the areas of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Drug repurposing is the process of discovering new therapeutic uses for existing drugs.

For more information, visit <https://nashpharmaceuticals.com/>.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Nash Pharmaceuticals Inc.
604.398.4175 ext 701
info@breathtechbiomedical.com
investors@breathtechbiomedical.com
www.breathtechbiomedical.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.